Therapy Areas: Oncology
IPA's BioStrand Business, BriaCell Enter Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
2 December 2022 - - Canadian biotherapeutic research and technology company IPA's (Immunoprecise Antibodies Ltd) (NASDAQ: IPA) BioStrand BV AI in silico discovery subsidiary has entered into a research collaboration and license agreement with clinical-stage biotechnology company BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT), specializing in targeted immunotherapies for cancer, the company said.

The collaboration will leverage BioStrand's LENSai software, built upon IPA's proprietary HYFT Universal Fingerprint technologies, and will focus on in silico antibody discovery to generate relevant clinical molecules for potential development.

Under the terms of the agreement, BioStrand and BriaCell will collaborate on the design, discovery, and development of anti-cancer antibodies.

Upon successful antibody discovery, BioStrand will receive an upfront payment of USD 500,000, and will be eligible to receive future success-based development milestones, including those for the submission of Investigational New Drugs, clinical milestone payments, and commercial royalties on net sales of products.

Further terms are not disclosed.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V.

The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery.

Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets.


Related Headlines